R. Han

发表

VPS34 suppression reverses osimertinib resistance via simultaneously inhibiting glycolysis and autophagy.

Chen Hu, Yong He, Li Li, 2021, Carcinogenesis.

Caveolin-1-mediated STAT3 activation determines electrotaxis of human lung cancer cells

Yong He, Kejun Zhang, Min Zhao, 2017, Oncotarget.

Brief Report: Effective treatment of lung adenocarcinoma harboring EGFR-activating mutation/T790M/cis-C797S triple mutations by brigatinib and cetuximab combination therapy.

N. Yang, Yongchang Zhang, Yong He, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Metformin Inhibits the IL-6-Induced Epithelial-Mesenchymal Transition and Lung Adenocarcinoma Growth and Metastasis

H. Long, Xiao-ming Cheng, Bo Zhu, 2014, PloS one.

Metformin Sensitizes EGFR-TKI–Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal

Yong He, Jianxin Jiang, Li Li, 2014, Clinical Cancer Research.

The Clinical Strategy to Overcome EGFR-TKI Acquired Resistance for NSCLC Patients

Ommega Internationals, Yong He, Li Li, 2016 .

Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1

Yong He, Li Li, Yubo Wang, 2020, Cell Death & Disease.

Metformin‐sensitized NSCLC cells to osimertinib via AMPK‐dependent autophagy inhibition

Yong He, Li Li, Yubo Wang, 2019, The clinical respiratory journal.

Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes.

Dong Wang, Yong He, Jianguo Sun, 2015, Cancer letters.

Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling

Y. Zhuang, Chen Hu, Xiaolin Tang, 2022, Communications Biology.

The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy.

P. Tian, Bing Yu, Yong He, 2020, Lung cancer.

Genetic Heterogeneity Between Paired Primary and Brain Metastases in Lung Adenocarcinoma

Mengyao Wang, Lin Li, Yong He, 2020, Clinical Medicine Insights. Oncology.

Vorinostat and metformin sensitize EGFR-TKI resistant NSCLC cells via BIM-dependent apoptosis induction

Yong He, Li Li, Yubo Wang, 2017, Oncotarget.

The rational application of liquid biopsy based on next‐generation sequencing in advanced non‐small cell lung cancer

N. Yang, Yongchang Zhang, Yong He, 2022, Cancer medicine.

Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib.

Yong He, Li Li, Yubo Wang, 2018, Lung cancer.

Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non–small‐cell lung cancer

Yong He, Cheng Shen, Li Li, 2023, Cancer science.

Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway

Yong He, Kejun Zhang, Li Li, 2015, Oncotarget.

Diagnostic value and influencing factors of fractional exhaled nitric oxide in suspected asthma patients.

Yong He, Li Li, Yubo Wang, 2015, International journal of clinical and experimental pathology.

Surgery for giant emphysematous bullae: case report and a short literature review.

Yong He, Li Li, Rui Han, 2014, Journal of thoracic disease.

Metformin Combining PD-1 Inhibitor Enhanced Anti-Tumor Efficacy in STK11 Mutant Lung Cancer Through AXIN-1-Dependent Inhibition of STING Ubiquitination

Q. Ouyang, Chao-Feng Hou, Yong He, 2022, Frontiers in Molecular Biosciences.

Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial

Qi Zhou, Zhi Xu, Haidong Wang, 2019, Clinical Cancer Research.

First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent Treatments

Yong He, Z. Ding, Li Li, 2022, Clinical Medicine Insights. Oncology.

Applied electric fields suppress osimertinib-induced cytotoxicity via inhibiting FOXO3a nuclear translocation through AKT activation.

Chen Hu, Yong He, Kejun Zhang, 2020, Carcinogenesis.

Low BMI patients with advanced EGFR mutation-positive NSCLC can get a better outcome from metformin plus EGFR-TKI as first-line therapy: A secondary analysis of a phase 2 randomized clinical trial

Yubo Wang, Tingting He, Jie Zheng, 2023, Chinese medical journal pulmonary and critical care medicine.

Aspirin sensitizes osimertinib‐resistant NSCLC cells in vitro and in vivo via Bim‐dependent apoptosis induction

Chen Hu, Yong He, Li Li, 2020, Molecular oncology.

Biological Significance of 18F-FDG PET/CT Maximum Standard Uptake Value for Predicting EGFR Mutation Status in Non-Small Cell Lung Cancer Patients

Yong He, Rongbing Jin, Li Li, 2021, International journal of general medicine.

Biological Significance of F-FDG PET/CT Maximum Standard Uptake Value for Predicting EGFR Mutation Status in Non-Small Cell Lung Cancer Patients

Yong He, Rongbing Jin, Li Li, 2021 .

Diagnostic possibility of the combination of exhaled nitric oxide and blood eosinophil count for eosinophilic asthma

Yong He, Li Li, Yubo Wang, 2021, BMC Pulmonary Medicine.

A transcriptional miRNA-gene network associated with lung adenocarcinoma metastasis based on the TCGA database.

M. Fu, Yong He, Li Li, 2016, Oncology reports.

Predictive value of early kinetics of ctDNA combined with cfDNA and serum CEA for EGFR‐TKI treatment in advanced non‐small cell lung cancer

Di Wu, Chen Hu, Yong He, 2022, Thoracic cancer.

The efficacy of the combination of exhaled nitric oxide and blood eosinophil count in the diagnosis of asthma in China

Yong He, Li Li, Yubo Wang, 2020 .

Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway

Yong He, Kejun Zhang, Li Li, 2016, Oncotarget.

Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1

Yong He, Li Li, Yubo Wang, 2020, Cell Death & Disease.

The potential therapeutic regimen for overcoming resistance to osimertinib due to rare mutations in NSCLC

Yong He, Yubo Wang, Caiyu Lin, 2023, iScience.

Protective autophagy decreases lorlatinib cytotoxicity through Foxo3a-dependent inhibition of apoptosis in NSCLC

Yong He, R. Yu, Caiyu Lin, 2022, Cell death discovery.

Protective autophagy decreases lorlatinib cytotoxicity through Foxo3a-dependent inhibition of apoptosis in NSCLC

Di Wu, Yong He, Yong He, 2022, Cell Death Discovery.

Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer.

Caiyu Lin, Yuanyao Dou, Cong-hua Lu, 2024, Acta pharmacologica Sinica.

Hexokinases II‐mediated glycolysis governs susceptibility to crizotinib in ALK‐positive non‐small cell lung cancer

Yong He, Li Li, Yubo Wang, 2021, Thoracic cancer.

pH-responsive theranostic nanoplatform of ferrite and ceria co-engineered nanoparticles for anti-inflammatory

Di Wu, Yubo Wang, Yong He, 2022, Frontiers in Bioengineering and Biotechnology.

Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect

Caiyu Lin, Yuanyao Dou, Cong-hua Lu, 2024, Journal for ImmunoTherapy of Cancer.